Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
This was a randomized, multi-center, open-label clinical trial. Eligible patients were recruited from seven hospitals in China. On the basis of standard-of-care, patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) until discharge. Patients in control group received standard-of-care (consisting of oxygen therapy) alone until discharge.
Description: The proportion of patients with improved disease severity (by at least one scale) at day 2
Measure: The proportion of patients with improved disease severity at day 2 Time: from baseline to day 2Description: The proportion of patients with improved disease severity (by at least one scale) at day 3
Measure: The proportion of patients with improved disease severity at day 3 Time: from baseline to day 3Description: The proportion of patients with improved disease severity (by at least one scale) at the day before hospital discharge
Measure: The proportion of patients with improved disease severity at the day before hospital discharge Time: up to 14 days (from baseline to the day before hospital discharge)Description: The change from baseline in oxygen saturation at day 2.
Measure: The change from baseline in oxygen saturation at day 2. Time: from baseline to day 2Description: The change from baseline in oxygen saturation at day 3.
Measure: The change from baseline in oxygen saturation at day 3. Time: from baseline to day 3Description: The change from baseline in oxygen saturation at the day before hospital discharge.
Measure: The change from baseline in oxygen saturation at the day before hospital discharge Time: up to 14 days (from baseline to the day before hospital discharge)Description: The change from baseline in dyspnea scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2.
Measure: The change from baseline in dyspnea scale at day 2. Time: from baseline to day 2Description: The change from baseline in dyspnea scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3.
Measure: The change from baseline in dyspnea scale at day 3. Time: from baseline to day 3Description: The change from baseline in dyspnea scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge.
Measure: The change from baseline in dyspnea scale at the day before hospital discharge. Time: up to 14 days (from baseline to the day before hospital discharge)Description: The change from baseline in cough scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2
Measure: The change from baseline in cough scale at day 2 Time: from baseline to day 2Description: The change from baseline in cough scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3
Measure: The change from baseline in cough scale at day 3 Time: from baseline to day 3Description: The change from baseline in cough scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge
Measure: The change from baseline in cough scale at the day before hospital discharge Time: up to 14 days (from baseline to the day before hospital discharge)Description: The change from baseline in chest pain scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2.
Measure: The change from baseline in chest pain scale at day 2. Time: from baseline to day 2Description: The change from baseline in chest pain scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3.
Measure: The change from baseline in chest pain scale at day 3. Time: from baseline to day 3Description: The change from baseline in chest pain scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge.
Measure: The change from baseline in chest pain scale at the day before hospital discharge. Time: up to 14 days (from baseline to the day before hospital discharge)Description: The change from baseline in chest distress scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2.
Measure: The change from baseline in chest distress scale at day 2. Time: from baseline to day 2Description: The change from baseline in chest distress scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3.
Measure: The change from baseline in chest distress scale at day 3. Time: from baseline to day 3Description: The change from baseline in chest distress scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge.
Measure: The change from baseline in chest distress scale at the day before hospital discharge. Time: up to 14 days (from baseline to the day before hospital discharge)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports